20/20 Biolabs, Inc. Common Stock (AIDX) — Capital Reinvestment Ratio
Latest as of December 2022:
0.05x
20/20 Biolabs, Inc. Common Stock (AIDX) has a Capital Reinvestment Ratio of 0.05x as of December 2022, meaning it reinvests 0% of its operating cash flow ($5.80 Million) in capital expenditures ($261.79K). See AIDX free cash flow to operating cash ratio to measure how efficiently the company converts operating cash flow to free cash.
Capital Reinvestment Ratio
0.05x
Capex / Operating Cash Flow
Operating Cash Flow
$5.80 Million
USD
Capital Expenditures
$261.79K
USD
Data as of
Dec 2022
Most recent filing
20/20 Biolabs, Inc. Common Stock Capital Reinvestment Ratio (2022–2022)
This chart tracks 20/20 Biolabs, Inc. Common Stock's Capital Reinvestment Ratio across 1 annual periods.
Annual Capital Reinvestment Ratio for 20/20 Biolabs, Inc. Common Stock (2022–2022)
Year-by-year Capital Reinvestment Ratio for 20/20 Biolabs, Inc. Common Stock from 2022 to 2022. For live market cap and broader valuation context, see AIDX market cap.
| Year | Reinvestment Ratio | Operating CF (USD) | Capital Expenditures | YoY Change |
|---|---|---|---|---|
| 2022 | 0.05x | $5.80 Million | $261.79K | — |
Capital Reinvestment Ratio = ABS(Capital Expenditures) / Operating Cash Flow